Table 3

Estimated changes in lung cancer survival rates following the launch of targeted therapies (gefitinib and erlotinib) using interrupted time series and segmented regression models

InterceptBaseline trend
(95% CI)
Changes after the launch of gefitinib (2003)Changes after the launch of gefitinib and erlotinib (2006)
Level change
(95% CI)
Trend change
(95% CI)
Absolute change
(3 years later)
(95% CI)
Relative change
(3 years later)
(95% CI)
Level change
(95% CI)
Trend change
(95% CI)
Absolute change
(3 years later)
(95% CI)
Relative change
(3 years later)
(95% CI)
1-year survival rate (all)0.34780.0041
(0.0015 to 0.0067)
NS0.0135
(0.0096 to 0.0174)
0.0404
(0.0286 to 0.0522)
10.18%
(6.77% to 13.59%)
NSNS00.00%
2-year survival rate (all)0.2169NS−0.0138
(−0.0272 to −0.0004)
0.0189
(0.0171 to 0.0207)
0.0430
(0.0331 to 0.0528)
19.81%
(14.90% to 24.71%)
NSNS00.00%
1-year survival rate (male)0.3505NSNS0.0125
(0.0111 to 0.0139)
0.0375
(0.0333 to 0.0417)
10.70%
(9.34% to 12.06%)
NSNS00.00%
2-year survival rate (male)0.2165−0.0024
(−0.0046 to −0.0001)
−0.0206
(−0.0363 to 0.0049)
0.0158
(0.0130 to 0.0186)
0.0268
(0.0084 to 0.0452)
14.25%
(3.27% to 25.24%)
NSNS00.00%
1-year survival rate (female)0.35320.0110
(0.0071 to 0.0149)
−0.0455
(−0.0929 to 0.0019)
0.0392
(0.0213 to 0.0571)
0.0720
(0.0374 to 0.1065)
14.82%
(6.92% to 22.71%)
NS−0.0315
(−0.0513 to −0.0117)
−0.0945
(−0.1537 to −0.0354)
−13.34%
(−20.48% to −6.20%)
2-year survival rate (female)0.21740.0056
(0.0030 to 0.0083)
−0.0391
(−0.0795 to −0.0013)
0.0396
(0.0256 to 0.0536)
0.0861
(0.0514 to 0.1208)
31.12%
(15.64% to 46.60%)
NS−0.0227
(−0.0386 to −0.0068)
−0.0576
(−0.1170 to 0.0019)
−11.77%
(−22.36% to −1.18%)
  • 95% CI=estimate±(1.96*SE); all terms p<0.1 retained in models.

  • CI, confidence interval; NS, non-significant; SE, standard error.